Johnson & Johnson $JNJ Shares Purchased by Smartleaf Asset Management LLC

Key Points

• Smartleaf Asset Management LLC increased its stake in Johnson & Johnson by 10.4%, acquiring an additional 3,496 shares, bringing their total holdings to 37,066 shares valued at approximately $6.07 million.
• Johnson & Johnson reported earnings per share of $2.77 for the latest quarter, exceeding expectations and marking a 5.8% increase in revenue year-over-year, totaling $23.74 billion.
• The company also declared a quarterly dividend of $1.30 per share, with an annualized dividend of $5.20 and a dividend yield of 2.9%.

Smartleaf Asset Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,066 shares of the company's stock after acquiring an additional 3,496 shares during the quarter. Smartleaf Asset Management LLC's holdings in Johnson & Johnson were worth $6,068,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at $47,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $49,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Capital A Wealth Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at $50,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on JNJ shares. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Citigroup raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $0.1680 during trading hours on Friday, hitting $179.0980. 9,523,149 shares of the stock were exchanged, compared to its average volume of 8,657,504. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average of $163.48 and a 200 day moving average of $159.30. The company has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.